Type-A Nucleophosmine ( NPM1) Gene Mutation As A Prognostic Marker In AML Patients With Normal Karyotype

Acute myeloid leukemia (AML) is a clonal disease of hematopoiesis and is considered as the most common acute leukemia in adults. Several prognostic parameters have a major role in predicting prognosis in newly diagnosed AML patients. In particular, age, cytogenetics and early blast clearance have been found to be significantly related to complete remission rate and survival . Lactate dehydrogenase (LDH) and leukocyte number are further markers which are relevant for prognosis. However, there has been growing interest to use additional and more precise prognostic factors to estimate the response as early as possible .Among the commonly investigated molecular markers is nucleophosmin, a shuttling protein that has several established functions in normal cells, with branching interactions with other subcellular factors. Being one of the most mutated genes in AML, but data available so far are not sufficient to establish solid facts about its role in leukemogenesis.Mutation A, the commonest of its exon 12 identified mutations, is of particular interest. It has been studied in AML and, reaching a decision on impact of mutational status of NPM1 on evolution to AML is a promising path to better care and treatment, especially among patients with de novo AML and normal karyotype.This work aimed to study the prognostic value of NPM1mutation in acute myeloid leukemia patients with normal karyotype.The study was conducted in Clinical Pathology and Clinical Oncology Departments, Faculty of Medicine, Zagazig University